The objective of WP2 is to develop, undertake and analyse a survey on the practical implementation of the main aspects of European pharmaceutical legislation and the BSSD concerning therapeutic nuclear medicine.
A multi-tiered approach will be taken to evaluate the heterogeneity in the relevant provision for individualised patient-dose planning, including patient-specific dosimetry, radiopharmaceutical preparation, provision and involvement of the MPE, presence and implementation of national legislation and guidance pertaining to selected dose constraints, patient release criteria, and radioactive waste management.
To identify the existing gaps in implementing the above requirements and main barriers encountered in the development and use of therapeutic radiopharmaceuticals, the survey will target a number of European stakeholders across a breadth of aspects pertaining to nuclear medicine therapy. Identified stakeholders include industrial radiopharmaceutical companies, competent authorities and national regulators, national nuclear medicine and medical physics societies, national training schools, and individual experts working in the clinical field.
The survey can be accessed via this link until October 31st.